Analytical Data
-
Gene name
AIM1
- Application
-
Alternative Names
AIM1；AIM1；Beta/gamma crystallin domain-containing Protein 1
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9Y4K1
-
Expression Region
全长
-
AA Sequence
full
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
AIM1 (Absent in Melanoma 1) is a gene that has garnered significant interest in cancer research due to its connection with tumor suppression and potential implications in various malignancies, including melanoma. The AIM1 protein is a member of the AIM family, characterized by its role in cellular processes such as apoptosis and immune response modulation. Its expression is often downregulated in cancerous tissues, indicating a possible function in inhibiting tumor progression. Researchers have been investigating AIM1 as a target for therapeutic interventions, focusing on its mechanisms of action, interactions with other proteins, and influence on cellular pathways related to cancer development. Studies have also looked into its variant forms and how they may affect its functionality. As a result, AIM1 has emerged as a candidate for developing novel cancer treatments and biomarkers, providing hope for improved diagnostic and therapeutic strategies in oncology. Understanding AIM1's biological role and the pathways it affects could lead to enhanced therapeutic options for patients suffering from cancers where AIM1 expression is compromised.
